Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: Meta-regression analysis

Heart

Volumn 101, Issue 11, 2015, Pages 847-853

  Hourcade Potelleret, F ^a,c   Laporte, S ^b   Lehnert, V ^a   Delmar, P ^a   Benghozi, Renée ^a   Torriani, U ^a   Koch, R ^a   Mismetti, P ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG RESPONSE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; CORONARY DISEASE; DRUG EFFECTS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; TREATMENT OUTCOME;

CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY DISEASE; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84930669017     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306691     Document Type: Article

References (34)

1. Baigent C, Keech A, Kearney PM, et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Libby P. The forgotten majority. Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46:1225-8.
3. DeGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008;51:49-55.
4. Yusuf S, Hawken S, Ounpuu S, et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
5. Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11-20.
6. Sharrett AR, Ballantyne CM, Coady SA, et al., Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13.
7. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
8. Jacobs DR Jr, Mebane IL, Bangdiwala SI, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence. Am J Epidemiol 1990;131:32-47.
9. Di Angelantonio E, Sarwar N, Perry P, et al., Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
10. Barter P, Gotto AM, LaRosa JC, et al., Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med 2007;357:1301-10.
11. Van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42.
12. Miller GJ and Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975;1:16-19.
13. Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004;101:17-38.
14. SAS: Statistical Analysis System. Cary, NC, USA: SAS Institute Inc. http://www.sas.com
15. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2007. http://www.r-project.org
16. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. FIELD study investigators. Lancet 2005;366:1849-61.
17. Ismail-Beigi F, Craven T, Banerji MA, et al., ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-30.
18. Silbernagel G, Schöttker B, Appelbaum S, et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 2013;34:3563-71.
19. Riwanto M, Landmesser U. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res 2013;54:3227-43.
20. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.
21. Keene D, Price C, Shun-Shin MJ, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014;349:g4379.
22. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015;36:539-50.
23. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.
24. Van Capelleveen JC, Brewer HB, Kastelein JJ, et al. Novel therapies focused on the high-density lipoprotein particle. Circ Res 2014;114:193-204.
25. Kasai T, Miyauchi K, Kubota N, et al. Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis 2012;220:463-9.
26. Kajinami K, Akao H. Probucol: Can we step forward in atherosclerosis prevention with an old drug? Atherosclerosis 2012;221:34-5.
27. Zhong JK, Guo ZG, Li C, et al. Probucol alleviates atherosclerosis and improves high density lipoprotein function. Lipids Health Dis 2011;10:210.
28. Lu J, Hübner K, Nanjee MN, et al. An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway. PLoS Comput Biol 2014;10:e1003509.
29. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84.
30. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-23.
31. Moriyama Y, Okamura T, Inazu A, et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998;27:659-67.
32. Cannon CP, Shah S, Dansky HM, et al., Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.
33. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109.
34. Krumholz HM. Emphasizing the burden of proof: The American College of Cardiology 2008 Expert Panel Comments on the ENHANCE Trial. Circ Cardiovasc Qual Outcomes 2010;3:565-7.